Actinium-225 in targeted Alpha-particle therapeutic applications

Current Radiopharmaceuticals

Volumn 4, Issue 4, 2011, Pages 306-320

  Scheinberg, David A ^a   Mcdevitt, Michael R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Actinium 225; Alpha particle emitter; Carbon nanotubes; Monoclonal antibody; Nanomaterials; Radioimmunotherapy; Targeted therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ACTINIUM 225; BISMUTH 213; CARBON NANOTUBE; CHELATING AGENT; FULLERENE DERIVATIVE; METAL ION; METALLOFULLERENE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; RADIOISOTOPE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALPHA RADIATION; ARTICLE; BIOLUMINESCENCE; CANCER RADIOTHERAPY; CANCER THERAPY; CELL SIZE; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DOSIMETRY; DRUG DISTRIBUTION; DRUG HALF LIFE; HUMAN; IMAGING SYSTEM; LINEAR ENERGY TRANSFER; LIPOSOMAL DELIVERY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RADIATION INJURY;

EID: 80052230219     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471011104040306     Document Type: Article

References (69)

1. Milenic, D.E.; Brechbiel, M.W. Targeting of radio-isotopes for cancer therapy. Cancer Biol. & Ther., 2004, 3, 361-370.
2. Nikula, T.K.; McDevitt, M.R.; Finn, R.D.; Wu, C.; Kozak, R.W.; Garmestani, K.; Brechbiel, M.W.; Curcio, M.J.; Pippin, C.G.; Tiffany- Jones, L.; Geerlings, M.W. Sr.; Apostolidis, C. Molinet, R.; Geerlings, M.W. Jr.; Gansow, O.A.; Scheinberg, D.A. Alphaemitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J. Nucl. Med., 1999, 40, 166-176.
3. McDevitt, M.R.; Sgouros, G.; Finn, R.D.; Humm, J.L.; Jurcic, J.G.; Larson, S.M.; Scheinberg, D.A. Radioimmunotherapy with alphaemitting nuclides. Eur. J. Nucl. Med., 1998, 25, 1341-1351.
4. Miederer, M.; Scheinberg, D.A.; McDevitt, M.R. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha- particle therapy applications. Adv. Drug. Deliv. Rev., 2008, 60, 1371-1382
5. Friesen, C.; Glatting, G.; Koop, B.; Schwarz, K.; Morgenstern, A.; Apostolidis, C.; Debatin, K.M.; Reske, S.N. Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res., 2007, 67, 1950-1958.
6. McDevitt, M.R.; Ma, D.; Lai, L.T.; Simon, J.; Borchardt, P.; Frank, R.K.; Wu, K.; Pellegrini, V.; Curcio, M.J.; Miederer, M.; Bander, N.H.; Scheinberg, D.A. Tumor therapy with targeted atomic nanogenerators. Science, 2001, 294, 1537-1540.
7. McDevitt, M.R.; Barendswaard, E.; Ma, D.; Lai, L.; Curcio, M.J.; Sgouros, G.; Ballangrud, A.M.; Yang, W.H.; Finn, R.D.; Pellegrini, V.; Geerlings, M.W. Jr.; Lee, M.; Brechbiel, M.W.; Bander, N.H.; Cordon-Cardo, C.; Scheinberg, D.A. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res., 2000, 60 6095-6100.
8. Weast, R.C. The CRC Handbook of Chemistry and Physics, 6th ed.; CRC Press Inc.: Boca Raton, FL, 1985.
9. Adloff, J.P. The centenary of a controversial discovery: actinium. Radiochim. Acta, 2000, 123-127.
10. [Methods for the production of Ac-225 and Bi-213 for alpha immunotherapy. ITU Annual Report 1995-(EUR 16368)-Basic Actinide Research: Karlsruhe, 1995; pp. 55-56.
11. Koch, L.; Apostolidis, C.; Molinet, R.; Nicolaou, G.; Janssens, W.; Schweikert, H. Production of Bi-213 and Ac-225. Alpha-Immuno-97 Symposium, Karlsruhe, Germany, 1997.
12. Mirzadeh, S. Generator-produced alpha-emitters. Appl. Radiat. Isot., 1998, 49, 345-349.
13. Apostolidis, C.; Molinet, R.; Rasmussen, G.; Morgenstern, A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal. Chem., 2005, 77, 6288-6291.
14. Boll, R.A.; Malkemus, D.; Mirzadeh, S. Production of actinium-225 for alpha particle mediated radioimmunotherapy. Appl. Radiat. Isot., 2005, 62, 667-679.
15. Boll, R.A.; Mirzadeh, S.; Kennel, S.J.; DePaoli, D.W.; Webb, O.F. Bi-213 for alpha particle mediated radioimmunotherapy, J. Label. Compds. Radiopharm., 1997, 40, 341-343.
16. McDevitt, M.R.; Finn, R.D.; Ma, D.; Larson, S.M.; Scheinberg, D.A. Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. J. Nucl. Med., 1999, 40, 1722-1727.
17. McDevitt, M.R.; Finn, R.D.; Sgouros, G.; Ma, D.; Scheinberg, D.A. An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation. Appl. Radiat. Isot., 1999, 50, 895-904.
18. Jurcic, J.G.; Larson, S.M.; Sgouros, G.; McDevitt, M.R.; Finn, R.D.; Divgi, C.R.; Ballangrud, A.M.; Hamacher, K.A.; Ma, D.; Humm, J.L.; Brechbiel, M.W.; Molinet, R.; Scheinberg, D.A. Targeted alpha particle immunotherapy for myeloid leukemia. Blood, 2002, 100, 1233-1239.
19. Jurcic, J.G.; McDevitt, M.R.; Pandit-Taskar, N.; Divgi, C.R.; Finn, R.D.; Sgouros, G.; Apostolidis, C.; Chanel, S.; Larson, S.M.; Scheinberg, D.A. Alpha-particle immunotherapy for acute myeloid leukemia (AML) with Bismuth-213 and Actinium-225. Cancer Biother. Radiopharm., 2006, 21(4), 396.
20. Geerlings, M.W.; Kaspersen, F.M.; Apostolidis, C.; van der Hout, R. The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy. Nucl. Med. Comm., 1993, 14, 121-125.
21. Khalkin, V.A.; Tsoupka-Sitnikoz, V.V.; Zaitseva, N.G. Radionuclides for radiotherapy. Properties, preparation and application of Actinium-225. Radiochem., 1997, 39, 483-492.
22. Lambrecht, R.M.; Tomiyoshi, K.; Sekine, T. Radionuclide Generators. Radiochim. Acta, 1997, 77, 103-123.
23. Apostolidis, C.; Molinet, R.; McGinley, J.; Abbas, K.; Mollenbeck, J.; Morgenstern, A. Cyclotron production of Ac-225 for targeted alpha therapy. Appl. Radiat. Isot., 2005, 62, 383-387.
24. Diamond, R.; Street, K.; Seaborg, G.T. An ion-exchange study of possible hybridized 5f bonding in the actinides. J. Am. Chem. Soc., 1954, 76, 1461-1469.
25. Yamana, H.; Mitsugashira, T.; Shiokawa, Y.; Sato, A.; Suzuki, S. Possibility of the existence of divalent actinium in aqueous solution. J. Radioanal. Chem., 1983, 76, 19-26.
26. Kulikov, E.V.; Novgorodov, A.F.; Schumann, D. Hydrolysis of 225-Actinium trace quantities. J. Radioanal. Nucl. Chem. Letters, 1992, 164, 103-108.
27. McDevitt, M.R.; Ma, D.; Simon, J.; Frank, R.K.; Scheinberg, D.A. Design and synthesis of 225Ac radioimmunopharmaceuticals. Appl. Radiat. Isot., 2002, 57, 841-847.
28. Beyer, G.J.; Bergmann, R.; Schomacker, K.; Rosch, F.; Schafer, G. Comparison of the biodistribution of 225Ac and radio-lanthanides as citrate complexes. Isopenpraxis, 1990, 3, 111-114.
29. Beyer, G.J.; Offord, R.; Kunzi, G.; Aleksandrova, Y.; Ravn, U.; Jahn, S.; Barker, J.; Tengblad, O.; Lindroos, M. The influence of EDTMP-concentration on the biodistribution of radio-lanthanides and 225Ac in tumor-bearing mice. Nucl. Med. Biol., 1997, 24, 367-372.
30. Davis, I.A.; Glowienka, K.A.; Boll, R.A.; Deal, K.A.; Brechbiel, M.W.; Stabin, M.; Bochsler, P.N.; Mirzadeh, S.; Kennel, S.J. Comparison of 225-actinium chelates: tissue distribution and radiotoxicity. Nucl. Med. Biol., 1999, 26, 581-589.
31. Deal, K.A.; Davis, I.A.; Mirzadeh, S.; Kennel, S.J.; Brechbiel, M.W. Improved in vivo stability of actinium-225 macrocyclic complexes. J. Med. Chem., 1999, 42, 2988-2992.
32. Kaspersen, F.M.; Bos, E.; Doornmalen, A.V.; Geerlings, M.W.; Apostolidis, C.; Molinet, R. Cytotoxicity of 213Bi- and 225Acimmunoconjugates. Nucl. Med. Comm., 1995, 16, 468-476.
33. Chappell, L.L.; Deal, K.A.; Dadachova, E.; Brechbiel, M.W. Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for 225Ac-radioimmunotherapy applications. Bioconjug. Chem., 2000, 11, 510-519.
34. Kennel, S.J.; Chappell, L.L.; Dadachova, K.; Brechbiel, M.W.; Lankford, T.K.; Davis, I.A.; Stabin, M.; Mirzadeh, S. Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors. Cancer Biother. Radiopharm., 2000, 15, 235-244.
35. Kennel, S.J.; Brechbiel, M.W.; Milenic, D.E.; Schlom, J.; Mirzadeh, S. Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49. Cancer Biother. Radiopharm., 2002, 17, 219-231.
36. Borchardt, P.E.; Yuan, R.R.; Miederer, M.; McDevitt, M.R.; Scheinberg, D.A. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res., 2003, 63, 5084-5090.
37. Miederer, M.; McDevitt, M.R.; Sgouros, G.; Kramer, K.; Cheung, N.K.; Scheinberg, D.A. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J. Nucl. Med., 2004, 45, 129-137.
38. Miederer, M.; McDevitt, M.R.; Borchardt, P.; Bergman, I.; Kramer, K.; Cheung, N.K.; Scheinberg, D.A. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alphaemitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin. Cancer Res., 2004, 10, 6985-6992.
39. Ballangrud, A.M.; Yang, W.H.; Palm, S.; Enmon, R.; Borchardt, P.E.; Pellegrini, V.A.; McDevitt, M.R.; Scheinberg, D.A.; Sgouros, G. Alpha-particle emitting atomic generator (Actinium-225)- labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin. Cancer Res., 2004, 10, 4489-4497.
40. Singh Jaggi, J.; Henke, E.; Seshan, S.V.; Kappel, B.J.; Chattopadhyay, D.; May, C.; McDevitt, M.R.; Nolan, D.; Mittal, V.; Benezra, R.; Scheinberg, D.A. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS ONE, 2007, 2, 267.
41. Escorcia, F.E.; Henke, E.; McDevitt, M.R.; Villa, C.H.; Smith- Jones, P.; Blasberg, R.G.; Benezra, R.; Scheinberg, D.A. Selective killing of tumor neo-vasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res., 2010, 70(22), 9277-9286.
42. Nolan, D.J.; Ciarrocchi, A.; Mellick, A.S.; Jaggi, J.S.; Bambino, K.; Gupta, S.; Heikamp, E.; McDevitt, M.R.; Scheinberg, D.A.; Benezra, R.; Mittal, V. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes & Dev., 2007, 21, 1546-1558.
43. Song, H.; Hobbs, R.F.; Vajravelu, R.; Huso, D.L.; Caroline Esaias C.; Apostolidis, C.; Morgenstern, A.; Sgouros, G. Radioimmunotherapy of breast cancer metastases with α-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res., 2009, 69(23), 8941-8948.
44. Miederer, M.; Henriksen, G.; Alke, A.; Mossbrugger, I.; Quintanilla- Martinez, L.; Senekowitsch-Schmidtke, R.; Essler, M. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res., 2008, 14(11), 3555-3561.
45. McDevitt, M.R.; Chattopadhyay, D.; Kappel, B.J.; Jaggi, J.S.; Schiffman, S.R.; Antczak, C.; Njardarson, J.T.; Brentjens, R.; Scheinberg, D.A. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J. Nucl. Med., 2007, 48, 1180-1189.
46. Ruggiero, A.; Villa, C.H.; Holland, J.P.; Sprinkle, S.R.; May, C.; Lewis, J.S.; Scheinberg, D.A.; McDevitt, M.R. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int. J. Nanomed., 2010, 5, 783-802.
47. McDevitt, M.R.; Chattopadhyay, D.; Jaggi, J.S.; Finn, R.D.; Zanzonico, P.B.; Njardarson, J.T.; Scheinberg, D.A. Positron-emission tomographic (PET) imaging of soluble carbon nanotubes in mice. PLoS ONE, 2007, 2, 907.
48. Ruggiero, A.; Villa, C.H.; Bander, E.; Rey, D.A.; Bergkvist, M.; Batt, C.A.; Manova-Todorova, K.; Deen, W.M.; Scheinberg, D.A.; McDevitt, M.R. Paradoxical glomerular filtration of carbon nanotubes. Proc. Natl. Acad. Sci. U S A, 2010, 107(27), 12369-12374.
49. Akiyama, K.; Haba, H.; Sueki, K.; Tsukada, K.; Asai, M.; Toyoshima, A.; Nagame, Y.; Katada, M. Ac-225 metallofullerene: toward Ac-225 nanogenerator in fullerene. Chem. Lett., 2009, 38(10), 978-979.
50. Akiyama, K.; Haba, H.; Tsukada, K.; Asai, M.; Toyoshima, A.; Sueki, K.; Nagame, Y.; Katada, M. A metallofullerene that encapsulates Ac-225. J. Radioanal. Nucl. Chem., 2009, 280(2), 329-331.
51. Sofou, S.; Thomas, J.L.; Lin, H.Y.; McDevitt, M.R.; Scheinberg, D.A.; Sgouros, G. Engineered liposomes for potential alphaparticle therapy of metastatic cancer. J. Nucl. Med., 2004, 45(2), 253-260.
52. Sofou, S.; Kappel, B.J.; Jaggi, J.S.; McDevitt, M.R.; Scheinberg, D.A.; Sgouros, G. Enhanced retention of the alpha-particle emitting daughters of actinium-225 by liposome carriers. Bioconjug. Chem., 2007, 18(6), 2061-2067.
53. Chang, M.Y.; Seideman, J.; Sofou, S. Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases. Bioconjug. Chem., 2008, 19(6), 1274-1282.
54. Sofou, S.; Enmon, R.; Palm, S.; Kappel, B.; Zanzonico, P.; McDevitt, M.R.; Scheinberg, D.A.; Sgouros, G. Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer. J. Liposome Res., 2010, 20(4), 330-340.
55. Sgouros, G.; Ballangrud, Å.M.; Jurcic, J.G.; McDevitt, M.R.; Humm, J.L.; Erdi, Y.E.; Mehta, B.M.; Finn, R.D.; Larson, S.M.; Scheinberg, D.A. Pharmacokinetics and dosimetry of an alphaparticle emitter labeled antibody [Bi-213]HuM195 (anti-CD33) in patients with leukemia. J. Nucl. Med., 1999, 40, 1935-1946.
56. Ruggiero, A.; Holland, J.P.; Lewis, J.S.; Grimm, J. Cerenkov luminescence imaging of medical isotopes. J. Nucl. Med., 2010, 51, 1123-1130.
57. Jaggi, J.S.; Kappel, B.J.; McDevitt, M.R.; Sgouros, G.; Flombaum, C.D.; Cabassa, C.; Scheinberg, D.A. Efforts to control the errant products of a targeted in vivo generator. Cancer Res., 2005, 65, 4888-4895.
58. Finn, R.; McDevitt, M.R.; Sheh, Y.; Lom, C.; Qiao, J.; Cai, S.; Burnazi, E.; Nacca, A.; Pillarsetty, N.; Jaggi, J.; Scheinberg, D.A. Cyclotron production of cesium radionuclides as analogues for Francium-221 biodistribution. Nucl. Instrum. Meth., 2005, 241, 649-651.
59. Yuan, R.R.; Wong, P.; McDevitt, M.R.; Doubrovina, E.; Leiner, I.; Bornmann, W.; O'Reilly, R.; Pamer, E.G.; Scheinberg, D.A. Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood, 2004, 104, 2397-2402.
60. Jaggi, J.S.; Seshan, S.V.; McDevitt, M.R.; LaPerle, K.; Sgouros, G.; Scheinberg, D.A. Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters. J. Am. Soc. Nephrol., 2005, 16, 2677-2689.
61. Jaggi, J.S.; Seshan, S.V.; McDevitt, M.R.; Sgouros, G.; Hyjek, E.; Scheinberg, D.A. Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. Int. J. Radiat. Oncol. Biol. Phys., 2006, 64, 1503-1512.
62. Sgouros, G.; Roeske, J.C.; McDevitt, M.R.; Palm, S.; Allen, B.J.; Fisher, D.R.; Brill, A.B.; Song, H.; Howell, R.W.; Akabani, G. MIRD Pamphlet No. 22 - Radiobiology and dosimetry of alphaparticle emitters for targeted radionuclide therapy, 2010; pp. 1-105.
63. Sgouros, G.; Roeske, J.C.; McDevitt, M.R.; Palm, S.; Allen, B.J.; Fisher, D.R.; Brill, A.B.; Song, H.; Howell, R.W.; Akabani, G. MIRD Pamphlet No. 22 (Abridged): Radiobiology and dosimetry of a-particle emitters for targeted radionuclide therapy. J. Nucl. Med., 2010, 51, 311-328.
64. Hamacher, K.A.; Sgouros, G. A schema for estimating absorbed dose to organs following the administration of radionuclides with multiple unstable daughters: a matrix approach. Med. Phys., 1999, 26, 2526-2528.
65. Hamacher, K.A.; Den, R.B.; Den, E.I.; Sgouros, G. Cellular dose conversion factors for alpha-particle--emitting radionuclides of interest in radionuclide therapy. J. Nucl. Med., 2001, 42, 1216-1221.
66. Hamacher, K.A.; Sgouros, G. Theoretical estimation of absorbed dose to organs in radioimmunotherapy using radionuclides with multiple unstable daughters. Med. Phys., 2001, 28, 1857-1874.
67. J.G.; Caron, P.C.; Nikula, T.K.; Papadopoulos, E.B.; Finn, R.D.; Gansow, O.A.; Miller, W.H. Jr.; Geerlings, M.W.; Warrell, R.P. Jr.; Larson, S.M.; Scheinberg, D.A. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res., 1995, 55, 5908s-5910s.
68. Jurcic, J.G.; Divgi, C.R.; McDevitt, M.R.; Ma, D.; Sgouros, G.; Finn, R.D.; Larson, S.M.; Scheinberg, D.A. Potential for myeloab lation with yttrium-90 labeled HuM195 (anti-CD33): a Phase I trial in advanced myeloid leukemias. Blood, 1998, 92(10), 613A.
69. Rosenblat, T.L.; McDevitt, M.R.; Mulford, D.A.; Pandit-Taskar, N.; Divgi, C.R.; Panageas, K.S.; Mark, L.; Heaney, M.L.; Chanel, S.; Morgenstern, A.; Sgouros, G.; Larson, S.M.; Scheinberg, D.A.; Jurcic, J.G. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin. Can. Res., 2010, 16(21), 5303-5311.